These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35078968)

  • 1. A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
    Duan X; Shi R; Liu P; Huang Q; Wang F; Chen X; Feng H; Huang W; Xiao J; Yan J
    Signal Transduct Target Ther; 2022 Jan; 7(1):23. PubMed ID: 35078968
    [No Abstract]   [Full Text] [Related]  

  • 2. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
    Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
    Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
    Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
    Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The atomic portrait of SARS-CoV-2 as captured by cryo-electron microscopy.
    Fertig TE; Chitoiu L; Terinte-Balcan G; Peteu VE; Marta D; Gherghiceanu M
    J Cell Mol Med; 2022 Jan; 26(1):25-34. PubMed ID: 34904376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
    Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
    Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement.
    McCallum M; Czudnochowski N; Rosen LE; Zepeda SK; Bowen JE; Walls AC; Hauser K; Joshi A; Stewart C; Dillen JR; Powell AE; Croll TI; Nix J; Virgin HW; Corti D; Snell G; Veesler D
    Science; 2022 Feb; 375(6583):864-868. PubMed ID: 35076256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
    Ge J; Wang R; Ju B; Zhang Q; Sun J; Chen P; Zhang S; Tian Y; Shan S; Cheng L; Zhou B; Song S; Zhao J; Wang H; Shi X; Ding Q; Liu L; Zhao J; Zhang Z; Wang X; Zhang L
    Nat Commun; 2021 Jan; 12(1):250. PubMed ID: 33431856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses.
    Banach BB; Cerutti G; Fahad AS; Shen CH; Oliveira De Souza M; Katsamba PS; Tsybovsky Y; Wang P; Nair MS; Huang Y; Francino-Urdániz IM; Steiner PJ; Gutiérrez-González M; Liu L; López Acevedo SN; Nazzari AF; Wolfe JR; Luo Y; Olia AS; Teng IT; Yu J; Zhou T; Reddem ER; Bimela J; Pan X; Madan B; Laflin AD; Nimrania R; Yuen KY; Whitehead TA; Ho DD; Kwong PD; Shapiro L; DeKosky BJ
    Cell Rep; 2021 Oct; 37(1):109771. PubMed ID: 34587480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding.
    Lin S; Chen Z; Zhang X; Wen A; Yuan X; Yu C; Yang J; He B; Cao Y; Lu G
    Signal Transduct Target Ther; 2022 Feb; 7(1):56. PubMed ID: 35190526
    [No Abstract]   [Full Text] [Related]  

  • 13. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants.
    Ou J; Zhang Y; Wang Y; Zhang Z; Wei H; Yu J; Wang Q; Wang G; Zhang B; Wang C
    Signal Transduct Target Ther; 2022 Feb; 7(1):43. PubMed ID: 35140198
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.
    Park YJ; De Marco A; Starr TN; Liu Z; Pinto D; Walls AC; Zatta F; Zepeda SK; Bowen JE; Sprouse KR; Joshi A; Giurdanella M; Guarino B; Noack J; Abdelnabi R; Foo SC; Rosen LE; Lempp FA; Benigni F; Snell G; Neyts J; Whelan SPJ; Virgin HW; Bloom JD; Corti D; Pizzuto MS; Veesler D
    Science; 2022 Jan; 375(6579):449-454. PubMed ID: 34990214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
    Dogan M; Kozhaya L; Placek L; Gunter C; Yigit M; Hardy R; Plassmeyer M; Coatney P; Lillard K; Bukhari Z; Kleinberg M; Hayes C; Arditi M; Klapper E; Merin N; Liang BT; Gupta R; Alpan O; Unutmaz D
    Commun Biol; 2021 Jan; 4(1):129. PubMed ID: 33514825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.
    Mannar D; Saville JW; Zhu X; Srivastava SS; Berezuk AM; Tuttle KS; Marquez AC; Sekirov I; Subramaniam S
    Science; 2022 Feb; 375(6582):760-764. PubMed ID: 35050643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes.
    Sun D; Sang Z; Kim YJ; Xiang Y; Cohen T; Belford AK; Huet A; Conway JF; Sun J; Taylor DJ; Schneidman-Duhovny D; Zhang C; Huang W; Shi Y
    Nat Commun; 2021 Aug; 12(1):4676. PubMed ID: 34344900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.
    Kwarteng A; Asiedu E; Sylverken AA; Larbi A; Sakyi SA; Asiedu SO
    Infect Genet Evol; 2021 Jul; 91():104815. PubMed ID: 33774178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the molecular mechanism of SARS-CoV-2 antibodies.
    Jin D; Wei J; Sun J
    Biochem Biophys Res Commun; 2021 Aug; 566():45-52. PubMed ID: 34116356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.